Drugs targeting Bcl-2 family members as an emerging strategy in cancer
- 8 September 2010
- journal article
- review article
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 12, e28
- https://doi.org/10.1017/s1462399410001572
Abstract
Inhibiting apoptosis is widely accepted as a necessary step in the transition from normal to cancer cells, and most cancer therapies exert their effects by indirectly reversing this process. Commitment to apoptosis is caused by permeabilisation of the outer mitochondrial membrane – a process regulated by the binding between different members of the Bcl-2 family. Furthermore, Bcl-2 family members also bind to the endoplasmic reticulum, where they modify processes such as the unfolded-protein response and autophagy that also cause or modify different types of cell death. With the growing understanding of the importance of the Bcl-2 family as crucial regulators of the decision to initiate apoptosis, much effort has been directed at developing small molecules that modify function by directly binding to Bcl-2 proteins. Preclinical experiments have confirmed that these agents kill cancer cells and overcome chemotherapy resistance. Two of these drugs are in the initial stages of clinical development (ABT-263 and obatoclax), and early results show clinical efficacy at tolerable doses. Important questions for the future include the role of these drugs as monotherapy versus combination therapy with other anticancer drugs, and the related issue of the relative toxicity to cancerous versus normal cells.Keywords
This publication has 98 references indexed in Scilit:
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1The EMBO Journal, 2009
- The role of autophagy in tumour development and cancer therapyExpert Reviews in Molecular Medicine, 2009
- Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptorBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- BAX Inhibitor-1 Is a Negative Regulator of the ER Stress Sensor IRE1αMolecular Cell, 2009
- Essential role for Nix in autophagic maturation of erythroid cellsNature, 2008
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranesApoptosis, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- The Hallmarks of CancerCell, 2000